Aspen Aerogels (ASPN) Misses Q3 EPS by 4c; Trims Outlook

Aspen Aerogels (NYSE: ASPN) reported Q3 EPS of ($0.13), $0.04 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $29.05 million.

GUIDANCE:

Aspen Aerogels sees FY2016 EPS of ($0.46)-($0.41), versus prior guidance of ($0.37)-($0.30) and the consensus of ($0.31). Aspen Aerogels sees FY2016 revenue of $118-121 million, versus prior guidance of $117-125 million and the consensus of $120.0 million.

For earnings history and earnings-related data on Aspen Aerogels (ASPN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Workhorse Group (WKHS) Misses Q2 EPS by 77c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c